FTase inhibitors in clinical trials
| Compound . | Phase . | Malignancy . | Status . | Protocol ID . |
|---|---|---|---|---|
| R115777 | I | Solid advanced tumors | Completed | NCI-97-C-0086B* |
| R115777 | I | Refractory solid tumors (children) | Active | NCI-98-C-0141* |
| R115777 | I | Refractory or recurrent acute leukemia or | Active | MSGCC-9802 |
| accelerated or blastic phase chronic | NCI-T99-0030* | |||
| myeloid leukemia | MSGCC-0398115 | |||
| URCC-980300 | ||||
| R115777 | I | Advanced cancer | Active | UTHSC-9785011335 |
| NCI-V98-1501 | ||||
| JRF-R115777 | ||||
| SACI-IDD-98-03 | ||||
| L-778,123 | I | Refractory or recurrent solid tumors or | Active | MSKCC-98116 |
| lymphomas | NCI-G99-1572* | |||
| MERCK-003-04 | ||||
| SCH66336 | I | Advanced cancer | Active | MSKCC-99020 |
| NCI-G99-1540* | ||||
| SPRI-C98-564-01 | ||||
| SCH66336 | II | Metastatic adenocarcinoma of the | Active | MSKCC-98115 |
| pancreas | NCI-G99-1571* | |||
| SPRI-C98-545-12 | ||||
| SCH66336 | II | Metastatic adenocarcinoma of the | Active | CWRU-SCH-1298 |
| pancreas | NCI-G99-1534* | |||
| SPRI-C98-545-18 | ||||
| SCH66336 | II | Metastatic adenocarcinoma of | Not yet active | UCLA-9906030 |
| the pancreas refractory to | NCI-G99-1610* | |||
| gemcitabine | SPRI-P00346 | |||
| SCH66336 | II | Previously treated, inoperable, locally | Not yet active | CAN-NCIC-IND128 |
| advanced, or metastatic transitional | SPRI-CAN-NCIC-IND128 | |||
| cell carcinoma of the bladder |
| Compound . | Phase . | Malignancy . | Status . | Protocol ID . |
|---|---|---|---|---|
| R115777 | I | Solid advanced tumors | Completed | NCI-97-C-0086B* |
| R115777 | I | Refractory solid tumors (children) | Active | NCI-98-C-0141* |
| R115777 | I | Refractory or recurrent acute leukemia or | Active | MSGCC-9802 |
| accelerated or blastic phase chronic | NCI-T99-0030* | |||
| myeloid leukemia | MSGCC-0398115 | |||
| URCC-980300 | ||||
| R115777 | I | Advanced cancer | Active | UTHSC-9785011335 |
| NCI-V98-1501 | ||||
| JRF-R115777 | ||||
| SACI-IDD-98-03 | ||||
| L-778,123 | I | Refractory or recurrent solid tumors or | Active | MSKCC-98116 |
| lymphomas | NCI-G99-1572* | |||
| MERCK-003-04 | ||||
| SCH66336 | I | Advanced cancer | Active | MSKCC-99020 |
| NCI-G99-1540* | ||||
| SPRI-C98-564-01 | ||||
| SCH66336 | II | Metastatic adenocarcinoma of the | Active | MSKCC-98115 |
| pancreas | NCI-G99-1571* | |||
| SPRI-C98-545-12 | ||||
| SCH66336 | II | Metastatic adenocarcinoma of the | Active | CWRU-SCH-1298 |
| pancreas | NCI-G99-1534* | |||
| SPRI-C98-545-18 | ||||
| SCH66336 | II | Metastatic adenocarcinoma of | Not yet active | UCLA-9906030 |
| the pancreas refractory to | NCI-G99-1610* | |||
| gemcitabine | SPRI-P00346 | |||
| SCH66336 | II | Previously treated, inoperable, locally | Not yet active | CAN-NCIC-IND128 |
| advanced, or metastatic transitional | SPRI-CAN-NCIC-IND128 | |||
| cell carcinoma of the bladder |
Three orally bioavailable FTase inhibitors have entered several phase I/II clinical trials. Most of these trials are National Cancer Institute–sponsored (*). The malignancies comprise a wide variety of human solid tumors (eg, primary brain tumors such as gliomas, neurofibromas, neurofibrosarcomas and malignant schwannomas, neuroblastomas, Wilms tumors, germ cell tumors, adenocarcinomas of the pancreas) and hematopoietic diseases such as acute leukemias and chronic myeloid leukemia in acceleration and blastic phase.